Identification and pharmacological characterization of SRBP-2: A novel SR31747A-binding protein

Cancer Research

Volumn 63, Issue 16, 2003, Pages 4809-4818

  Vidal, Hubert ^a   Mondesert, Guillaume ^a   Galiègue, Sylvaine ^a   Carrière, Dominique ^a   Dupuy, Pascal Henri ^a   Carayon, Pierre ^a   Combes, Thérèse ^a   Bribes, Estelle ^a   Simony Lafontaine, Joëlle ^b   Kramar, Andrew ^b   Loison, Gérard ^a   Casellas, Pierre ^a  

^a SANOFI   (France)

^b CENTRE VAL D AURELLE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING PROTEIN; COMPLEMENTARY DNA; ISOMERASE; LIGAND; MESSENGER RNA; N CYCLOHEXYL N ETHYL 3 (3 CHLORO 4 CYCLOHEXYLPHENYL) 2 PROPENYLAMINE; POLYCLONAL ANTIBODY; PROTEIN; SR 31747A BINDING PROTEIN 1; SR 31747A BINDING PROTEIN 2; TAMOXIFEN; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ARTICLE; BINDING SITE; BRAIN; CELL NUCLEUS MEMBRANE; CELL PROLIFERATION; CELLULAR DISTRIBUTION; COMPUTER MODEL; CONTROLLED STUDY; ENDOPLASMIC RETICULUM; HUMAN; HUMAN CELL; LIVER; NORTHERN BLOTTING; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROGNOSIS; TUMOR BIOPSY; TUMOR CELL;

AMINO ACID SEQUENCE; ANIMALS; BASE SEQUENCE; BREAST NEOPLASMS; CARRIER PROTEINS; FEMALE; HUMANS; IN SITU HYBRIDIZATION; IN SITU HYBRIDIZATION, FLUORESCENCE; MICE; MOLECULAR SEQUENCE DATA; PROGNOSIS; RABBITS; RECEPTORS, OPIOID; RECEPTORS, SIGMA; RNA, MESSENGER; STEROID ISOMERASES; TUMOR CELLS, CULTURED;

EID: 0042440982     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Casellas, P., Bourrié, B., Canat, X., Carayon, P., Buisson, I., Paul, R., Brelière, J. C., and Le Fur, G. Immunopharmacological profile of SR 31747: in vitro and in vivo studies on humoral and cellular responses. J. Neuroimmunol., 52: 193-203. 1994.
2. Bourrié, B., Benoit, J. M., Derocq, J. M., Esclangon, M., Thomas, C. Le Fur, G., and Casellas, P. A sigma ligand. SR31747A, potently modulates staphylococcal enterotoxin B-induced cytokine production in mice. Immunology. 88: 389-393, 1996.
3. Carayon, P., Bouaboula, M., Loubet, J. F., Bourrié, B., Petitprètre, G., Le Fur, G., and Casellas, P. The sigma ligand SR 31747 prevents the development of acute graft-versus-host disease in mice by blocking IFN-γ and GM-CSF mRNA expression. Int. J. Immunopharmacol., 17: 753-761, 1995.
4. Derocq, J. M., Bourrié, B. Ségui, M., Le Fur, G., and Casellas, P. In vivo inhibition of endotoxin-induced pro-inflammatory cytokines production by the sigma ligand SR 31747. J. Pharmacol. Exp. Ther., 272: 224-230, 1995.
5. Silve, S., Leplatois, P., Josse, A., Dupuy, P. H., Lanau, C., Kaghad, M., Dhers, C., Picard, C., Rahier, A., Taton, M., Le Fur, G., Caput, D., Ferrara, P., and Loison, G. The immunosuppresant SR 31747 blocks cell proliferation by inhibiting a steroid isomerase in Saccharomyces cerevisiae. Mol. Cell. Biol., 16: 2719-2727, 1996.
6. Cinato, E., Péléraux, A., Silve, S., Galiègue, S., Dhers, C., Picard, C., Jbilo, O., Loison, G., and Casellas, P. A DNA microarray-based approach to elucidate the effects of the immunosuppressant SR31747A on gene expression in Saccharomyces cerevisiae. Gene Expr., 10: 213-230, 2002.
7. Labit-Lebouteiller, C., Jamme, M. F., David, M., Silve, S., Lanau, C., Dhers, C., Picard, C., Rahier, A., Taton, M., Loison, G., Caput, D., Ferrara, P., and Lupker, J. Antiproliferative effects of SR31747A in animal cell lines are mediated by inhibition of cholesterol biosynthesis at the sterol isomerase step. Eur. J. Biochem., 256: 342-349, 1998.
8. Berthois, Y., Bourrié, B., Galiègue, S., Vidal, H., Carayon, P., Martin, P. M., and Casellas, P. SR31747A is a sigma ligand exhibiting antitumoral activity both in vitro and in vivo. Br. J. Cancer, 88: 438-446, 2003.
9. Jbilo, O., Vidal, H., Paul, R., DeNys, N., Bensaid, M., Silve, S., Carayon, P., Davi, D., Galiègue, S., Bourrié, B., Guillemot, J. C., Ferrarra, P., Loison, G., Maffrand, J. P., Le Fur, G., and Casellas, P. Purification and characterization of the human SR31747A-binding protein. A nuclear membrane protein related to yeast sterol isomerase. J. Biol. Chem., 272: 27107-27115, 1997.
10. Kekuda, R., Prasad, P. D., Fei, Y. J., Leibach, F. H., and Ganapathy, V. Cloning and functional expression of the human type 1 sigma receptor (hsigmaR1). Biochem. Biophys. Res. Commun., 229: 553-558, 1996.
11. Hanner, M., Moebius, F. F., Weber, F., Grabner. M., Striessnig, J., and Glossmann, H. Phenylalkylamine Ca2+ antagonist binding protein. Molecular cloning, tissue distribution, and heterologous expression. J. Biol. Chem., 270: 7551-7557, 1996.
12. Silve, S., Dupuy, P. H., Labit-Lebouteiller, C., Kaghad, M., Chalon, P., Rahier, A., Taton, M., Lupker, J., Shire, D., and Loison, G. Emopamil-binding protein, a mammalian protein that binds a series of structurally diverse neuroprotective agents, exhibits delta8-delta7 sterol isomerase activity in yeast. J. Biol. Chem., 271: 22434-22440, 1996.
13. Dussossoy, D., Carayon, P., Belugou, S., Feraut, D., Bord, A., Goubet, C., Roque, C., Vidal, H., Combes, T., Loison, G., and Casellas, P. Colocalization of sterol isomerase and sigma(l) receptor at endoplasmic reticulum and nuclear envelope level. Eur. J. Biochem., 263: 377-386, 1999.
14. Al-Nabulsi, I., Mach, R. H., Wang, L. M., Wallen, C. A., Keng, P. C., Sten, K., Childers, S. R., and Wheeler, K. T. Effect of ploidy, recruitment, environmental factors, and tamoxifen treatment on the expression of sigma-2 receptors in proliferating and quiescent tumour cells. Br. J. Cancer, 81: 925-933. 1999.
15. Mach, R. H., Smith, C. R., Al-Nabusi, I., Whirett, B. R., Childers, S. R., and Wheeler, K. T. σ2 receptors as potential biomarkers of proliferation in breast cancer. Cancer Res., 57: 156-161, 1997.
16. Heng, H. H. Q., Squire, J., and Tsui, L. High-resolution mapping of mammalian genes by in situ hybridization to free chromatin. Proc. Natl. Acad. Sci. USA, 89: 9509-9513, 1992.
17. Heng, H. H., and Tsui, L. C. Modes of DAPI banding and simultaneous in situ hybridization. Chromosoma, 102: 325-332, 1993.
18. Elston, C. W., and Ellis, I. O. Pathological prognostic factors in breast cancer: experience from a large study with long-term follow-up. Histopathology, 19: 403-410, 1991.
19. Simony-Lafontaine, J., Esslimani, M., Bribes, E., Gourgou, S., Lequeux, N., Lavail, R., Grenier, J., Kramar, A., and Casellas, P. Immunocytochemical assessment of sigma-1 receptor and human sterol isomerase in breast cancer and their relationship with a series of prognostic factors. Br. J. Cancer, 82: 1958-1966, 2000.
20. Paul, R., Silve, S., De Nys, N., Dupuy, P. H., Labit-Le-Bouteiller, C., Rosenfeld, J., Ferrara, P., Le Fur, G., Casellas, P., and Loison, G. Both the immunosuppressant SR31747A and the antiestrogen tamoxifen bind to an emopamil-insensitive site of mammalian Δ8-Σ7 sterol isomerase. J. Pharm. Exp. Ther., 285: 1296-1302, 1998.
21. Moebius, F. F., Soellner, K. M., Fiechtner, B., Huck, C. W., Bonn, G., and Glossmann, H. Histidine77, glutamic acid81, glutamic acid123, threonine126, asparagine-194, and tryptophan197 of the human emopamil binding protein are required for in vivo sterol delta8-delta7 isomerization. Biochemistry, 38: 1119-1127, 1999.